# Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

> **NCT07421700** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pfizer** · enrollment: 132 (estimated)

## Conditions studied

- Urothelial Cancer
- Advanced/Metastatic Urothelial Cancer
- Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** PF-08634404
- **BIOLOGICAL:** Enfortumab Vedotin

## Key facts

- **NCT ID:** NCT07421700
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2027-12-06
- **Final completion:** 2028-09-05
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07421700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07421700, "Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07421700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*